ASCO: Chronic leukemia treatment transformation is cancer advance of the year
the ONA take:
The American Society of Clinical Oncology (ASCO) has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
Until recently, many patients with CLL had limited effective treatment options for their disease, but four newly Food and Drug Administration (FDA)-approved therapies will significantly alter the prognosis for patients with the disease.
Those drugs include: obinutuzumab, ofatumumab, ibrutinib, and idelalisib. Obinutuzumab and ofatumumab are each to be used in combination with standard chemotherapy for those with previously untreated CLL, while ibrutinib and idelalisib are for relapsed or refractory CLL. For older patients particularly, these new therapies may be their first chance at treatment as other therapies were toxic for many to tolerate.
According to the American Cancer Society, there was estimated to be 15,720 cases of CLL in 2014 and 4,600 deaths from CLL. CLL accounts for approximately one-third of new cases of leukemia and mainly occurs in older adults with the average age of diagnosis being 72 years.
The ASCO has announced that the transformation of treatment for CLL is its Cancer Advance of the Year.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|